Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

416 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD; PERFORM Study Investigators. Bousser MG, et al. Among authors: mattle hp. Lancet. 2011 Jun 11;377(9782):2013-22. doi: 10.1016/S0140-6736(11)60600-4. Epub 2011 May 25. Lancet. 2011. PMID: 21616527 Clinical Trial.
[Cerebral ischemia].
Mattle HP, Hennerici M. Mattle HP, et al. Ther Umsch. 2003 Sep;60(9):497-8. doi: 10.1024/0040-5930.60.9.497. Ther Umsch. 2003. PMID: 14579617 German. No abstract available.
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients.
Georgiadis D, Arnold M, von Buedingen HC, Valko P, Sarikaya H, Rousson V, Mattle HP, Bousser MG, Baumgartner RW. Georgiadis D, et al. Among authors: mattle hp. Neurology. 2009 May 26;72(21):1810-5. doi: 10.1212/WNL.0b013e3181a2a50a. Epub 2009 Mar 25. Neurology. 2009. PMID: 19321846 Free article.
Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici MG, Mattle HP, Rothwell PM; PERFORM Study Investigators. Bousser MG, et al. Among authors: mattle hp. Cerebrovasc Dis. 2009;27(5):509-18. doi: 10.1159/000212671. Epub 2009 Apr 16. Cerebrovasc Dis. 2009. PMID: 19372653 Free article. Clinical Trial.
The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K, Hennerici M, Mattle HP, Rothwell PM; PERFORM Study Investigators. Bousser MG, et al. Among authors: mattle hp. Cerebrovasc Dis. 2009;27(6):608-13. doi: 10.1159/000216835. Epub 2009 Apr 30. Cerebrovasc Dis. 2009. PMID: 19407444 Free article. Clinical Trial.
Heart rate is a prognostic risk factor for myocardial infarction: a post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack) study population.
Fox K, Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Hennerici MG, Mattle HP, Rothwell PM; PERFORM Study Investigators. Fox K, et al. Among authors: mattle hp. Int J Cardiol. 2013 Oct 9;168(4):3500-5. doi: 10.1016/j.ijcard.2013.04.206. Epub 2013 May 22. Int J Cardiol. 2013. PMID: 23706327 Clinical Trial.
416 results